← All trials
NCT04678739
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2020
- Primary completion
- Jan 30, 2021
- Completion date
- Feb 28, 2021
- First posted
- Dec 22, 2020
- Last posted
- Jan 1, 2021
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- M Abdur Rahim Medical College and HospitalLead sponsor
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityStudy chair
- Jiao Tong UniversityCollaborator
- Chattogram General HospitalCollaborator
- Cox's Bazar 250 Bed District Sadar HospitalCollaborator
- Jiao Tong UniversityCollaborator
- M Abdur Rahim Medical College HospitalStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.